CONCLUSIONS: Our data shows that use of LB in radical cystectomy is well tolerated and may significantly reduce LOS, decrease perioperative opioid requirements, and improve patientreported pain scores when compared to historical controls. Additional patient enrollment and evaluation is needed to demonstrate continued benefit of LB.
INTRODUCTION AND OBJECTIVES:
In well-selected patients with muscle invasive bladder cancer (MIBC), chemoradiation therapy (CRT) offers the potential for bladder preservation. Following a maximal transurethral resection of the bladder tumor (TURBT), CRT is given over 4-8 weeks with or without a mid-treatment TURBT to assess early response followed by consolidative treatment. We hypothesized that TraceIT, an injectable biocompatible hydrogel, is safe and feasible to be used as a temporary bladder wall fiducial marker placed at the time of TURBT to guide radiotherapy planning and daily image guidance in patients undergoing radiotherapy for bladder cancer.
METHODS: Cohort included 9 patients enrolled on an IRBapproved prospective single-arm, single institutional trial from 2017-2018 (n[9) and 3 retrospective patients treated with the same approach off-study. Eligibility included: MIBC planned to receive definitive radiotherapy. TraceIT hydrogel was injected around the circumference of the tumor bed at time of the pre-treatment TURBT and/or at time of midcourse reassessment. The primary endpoint was analysis of fiducial marker localization to assess day-to-day interfraction motion of the bladder tumor bed on low-dose cone-beam CT (CBCT) acquired daily in the treatment room for alignment. Toxicities were measured by CTCAE v4.
RESULTS: Eleven patients with T2N0M0 and one patient with T2N0M1 MIBC underwent definitive RT to a median total dose of 64.4 ] with 11 patients receiving concurrent chemotherapy. TraceIT was injected (0.3-0.5 mL each, 4-6 injection sites, total volume 2-3 mL) at the time of the pre-treatment TURBT in 11 patients, mid-treatment TURBT in 1, and both in 3. All patients demonstrated strong visibility of TraceIT on the initial radiation simulation CT-scan. All patients had excellent visibility of the markers on CBCT used for alignment on day 1 of RT. Visualization after week 5 of RT in the first few patients was noted to be moderate to poor and thus the volume of TraceIT injection was increased to 0.5 mL and repeat TraceIT injection was performed at the time of midcourse TURBT. Subsequent patients had excellent visibility of the markers on CBCT maintained through the last day of RT. No significant toxicities were observed related to TraceIT placement. CONCLUSIONS: Our initial experience supports the safety and feasibility of TraceIT hydrogel as an intravesical fiducial marker. This can aid target delineation for radiotherapy planning and also allow accurate daily image guidance and targeting of the bladder tumor bed site during radiation to account for daily anatomic variation and motion of the bladder.
Source of Funding: TraceITTm provided from Augmentix, Inc (Bedford, MA) to support this ongoing trial (NCT03125226).
MP38-14 TIME-TO-EVENT ANALYSIS OF 30-DAY SHORT-TERM COMPLICATIONS AFTER RADICAL CYSTECTOMY FOR URINARY BLADDER CANCER
Jakob Klemm, Michael Rink, Philipp Gild, Florian Janisch, Armin Soave, Roland Dahlem, Margit Fisch, Malte W. Vetterlein*, Hamburg, Germany INTRODUCTION AND OBJECTIVES: Given the lack of individual patient data addressing the timing of perioperative complications following major urological procedures, we aimed to provide granular time-to-event data for short-term adverse events following radical cystectomy (RC).
METHODS: We performed a meticulous digital chart review of patients undergoing RC between 2009-2017 at our institution. The updated EAU criteria of standardized reporting were met and we extracted and tabulated 30-day complications of each patient according to a predefined complication catalogue. Complications were ranked by the Clavien-Dindo classification (CDC) and the exact time interval from RC to each complication was calculated. We evaluated traditional morbidity endpoints and categorized complications according to the Memorial Sloan Kettering Cancer Center complication groups. Time-to-event analyses followed two steps: Firstly, we plotted the time to complication (in days) for each complication group to assess the chronological distribution of complication categories over the first 30 days after RC. Secondly, we evaluated whether timing of major complications (!CDC grade IIIa) differed when patients were stratified according to the CDC. Box-and-whisker diagrams were used as a visualization tool to depict time-to-event data.
RESULTS: Of 506 patients, 503 (99%) experienced a total of 2 485 short-term complications, of which the most common were genitourinary (24%), gastrointestinal (19%), and infectious (15%) complications. The timing of complication incidence across the different groups was very heterogeneous ( Figure 1A) .
Overall, major complications (!CDC grade IIIa) occurred in 78 patients (15%), translating into 23 (4.6%), 31 (6.1%), 12 (2.4%), and 12 (2.4%) patients suffering from a maximum CDC grade IIIa, IIIb, IVa, and V complication, respectively. Median time to major complications was 10 days . With exception of patients who died within 30 days of surgery (CDC grade V), median time to complication decreased with higher CDC grades ( Figure 1B) . CONCLUSIONS: Knowledge of the timing of adverse events is important to facilitate anticipation and informed discussion regarding expectations of the postoperative course. Further identification of risk factors may guide in improving patient-tailored care. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e539
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